126 reports of this reaction
2.0% of all DEXTROMETHORPHAN HYDROBROMIDE reports
#7 most reported adverse reaction
DIZZINESS is the #7 most commonly reported adverse reaction for DEXTROMETHORPHAN HYDROBROMIDE, manufactured by RB Health (US) LLC. There are 126 FDA adverse event reports linking DEXTROMETHORPHAN HYDROBROMIDE to DIZZINESS. This represents approximately 2.0% of all 6,398 adverse event reports for this drug.
Patients taking DEXTROMETHORPHAN HYDROBROMIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for DEXTROMETHORPHAN HYDROBROMIDE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for DEXTROMETHORPHAN HYDROBROMIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 126 FDA reports for DEXTROMETHORPHAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.0% of all adverse event reports for DEXTROMETHORPHAN HYDROBROMIDE, making it a notable side effect.
If you experience dizziness while taking DEXTROMETHORPHAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.